溶质载体有机阴离子转运体家族1成员A2（SLCO1A2）、溶质载体有机阴离子转运体家族1成员B1（SLCO1B1）和溶质载体有机阴离子转运体家族2成员B1（SLCO2B1）基因多态性影响间日疟原虫疟疾中氯喹和伯氨喹的治疗效果。
SLCO1A2, SLCO1B1 and SLCO2B1 polymorphisms influences chloroquine and primaquine treatment in Plasmodium vivax malaria.
作者信息
Sortica Vinicius A, Lindenau Juliana D, Cunha Maristela G, O Ohnishi Maria Deise, R Ventura Ana Maria, Ribeiro-Dos-Santos Ândrea Kc, Santos Sidney Eb, Guimarães Luciano Sp, Hutz Mara H
机构信息
Departamento de Genética, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
Laboratório de Microbiologia e Imunologia, Universidade Federal do Para, Belém, PA, Brazil.
出版信息
Pharmacogenomics. 2017 Oct;18(15):1393-1400. doi: 10.2217/pgs-2017-0077. Epub 2017 Oct 4.
AIM
The association of transporters gene polymorphisms with chloroquine/primaquine malaria treatment response was investigated in a Brazilian population.
PATIENTS & METHODS: Totally, 164 Plasmodium vivax malaria infected patients were included. Generalized estimating equations were performed to determine gene influences on parasitemia and/or gametocytemia clearance over treatment time.
RESULTS
Significant interaction between SLCO2B1 genotypes and treatment over time for parasitemia clearance rate on day 2 were observed (p = 0.002). SLCO1A2 and SLCO1B1 gene treatment over time interactions were associated with gametocytemia clearance rate (p = 0.018 and p = 0.024). ABCB1, ABCC4 and SLCO1B3 were not associated with treatment response.
CONCLUSION
The present work presents the first pharmacogenetic report of an association between chloroquine/primaquine responses with OATP transporters.
目的
在巴西人群中研究转运蛋白基因多态性与氯喹/伯氨喹疟疾治疗反应之间的关联。
患者与方法
共纳入164例间日疟原虫感染患者。采用广义估计方程来确定基因对治疗期间寄生虫血症和/或配子体血症清除率的影响。
结果
观察到SLCO2B1基因型与治疗时间之间在第2天寄生虫血症清除率方面存在显著交互作用（p = 0.002）。SLCO1A2和SLCO1B1基因与治疗时间的交互作用与配子体血症清除率相关（p = 0.018和p = 0.024）。ABCB1、ABCC4和SLCO1B3与治疗反应无关。
结论
本研究首次报道了氯喹/伯氨喹反应与有机阴离子转运多肽（OATP）转运蛋白之间关联的药物遗传学报告。
Zotero 插件